Our research program is focused on improving therapies for patients with lung cancer. We have made several contributions to identifying tumor mutation and cancer cell states that confer resistance to lung cancer therapies, including the highly adaptable and deadly subtype of lung cancer, small cell lung carcinoma. Supporting our group’s translational efforts is the development of large-scale clinomic datasets that integrate detailed clinical information, patient-derived xenografts, and multi-omic features. Our team routinely employs tools from genomics, bioinformatics, computational modeling, and tumor biology in our work.